Data presented at the 2012 European Congress of Psychiatry on Selincro™ demonstrate that alcohol dependent patients were able to reduce their total alcohol consumption by 2/3 on average after six months of treatment
· Phase III clinical data showed that patients treated with Selincro (nalmefene) were able to reduce their total alcohol consumption by 66% on average after six months of treatment · The effect is maintained and even improved after one year of treatment · Selincro has been shown to be safe and well tolerated · Selincro has a significant potential for helping individuals with alcohol dependence in reducing their alcohol consumption · Selincro is the first medicine aimed for the reduction of alcohol consumption in patients with alcohol dependence and it is currently undergoing